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Background
Recent data from immune checkpoint studies, including
studies of anti-PD1 and anti-PDL1 antibodies, suggest
that an inflammatory intratumoral milieu is required for
an optimal response to immune therapy. Serial biopsy
analyses from a phase 1 study demonstrate that trans-
formation of tumor cells with electroporation (EP) of
plasmid interleukin-12 (pIL-12) promotes this inflamma-
tory immune milieu. Here we present clinical response
data for 30 advanced melanoma patients (pts) treated
with pIL-12 EP in a phase 2 trial (OMS-I100). We also
present additional safety and more detailed biomarker
data demonstrating the promotion of pro-inflammatory
genes with pIL-12 EP therapy.
Methods
Thirty patients with stage IIIB-IV melanoma received up
to 4 cycles of pIL-12 EP into superficial cutaneous, sub-
cutaneous, and nodal lesions on days 1, 5 and 8 of each
12-week cycle. Tumor responses were evaluated using
modified RECIST criteria for cutaneous lesions. Adverse
events (AEs) were assessed using CTCAE version 4.
Alterations in transcription were assessed by comparing
pre- and post-treatment biopsies from treated lesions
using NanostringTM technology to identify pharmaco-
dynamic markers of downstream pathway activation and
to characterize cellular infiltration.
Results
The best overall response rate (BORR) by modified
RECIST in 29 evaluable pts was 31% (9/29), with 10%
(3/29) of pts achieving a CR. Regression of at least one
non-treated lesion was seen in 54% (13/24) of pts with
evaluable lesions. The most common treatment-related
adverse event (AE) reported was transient Grade 1/2
pain at the treatment site, reported in 87% (26/30) of
pts. Grade 3 adverse events were rare and included only
1 report of Grade 3 pain at the injection site. No grade
4 or higher adverse events were observed. Analysis of
tissue samples from patients treated with pIL-12 EP
showed a gene expression pattern consistent with down-
stream activation of NK cells and interferon-g-depen-
dent genes, including key genes responsible for tumor
inflammation, antigen processing and presentation
(APM).
Conclusions
pIL-12 EP monotherapy induces objective tumor
responses in a significant proportion of patients
(BORR 31%) and treatment was well tolerated. pIL-12
EP promotes the expression of pro-inflammatory genes
including genes required for antigen processing and
presentation. Regression of non-treated lesions sug-
gests successful induction of systemic anti-tumor
immune-mediated effects. Based on these data, further
investigation of pIL-12 EP both as a single agent, and
in combination with other therapies such as anti-PD1/
PD-L1, is warranted.
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